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Abstract
With increasing life expectancy, the epidemic of valvular heart disease, especially aortic stenosis, is be-
coming more prevalent. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative 
therapy for patients with significant aortic valve disease. It offers a less invasive procedure in compari-
son to surgical aortic valve replacement and an attractive substitute from the patient’s perspective. The 
evidence for TAVI in inoperable and high risk surgical patients is now established and in the intermedi-
ate risk group has been accumulating rapidly and is looking favourable for TAVI. 
However, the full ‘TAVI story’ is still unfolding. Technological advances in devices and delivery systems 
are evolving with the aim to improve the function and durability of TAVI and to simplify the procedure 
while enhancing safety. The incidence of vascular injury and pacemaker requirement post TAVI re-
mains an issue and further development in this regard is therefore of utmost importance, particularly 
as lower risk and potentially younger patients are treated. Moreover, the evidence concerning long-term 
durability of the TAVI prostheses continues to accumulate. Whilst TAVI is proving to be an invaluable 
tool for inoperable and high risk patients, more trial evidence is needed before it encompases lower risk 
populations and moreover, its use as a first line treatment worldwide in most healthcare systems is 
limited by the costs associated with the prosthesis. (Cardiol J 2017; 24, 2: 206–215)
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Introduction
Life expectancy in Europe is still on the rise. 
In 2000, the average life expectancy in the United 
Kingdom was 78 years but by 2013 it reached 81.1 
years [1]. With advancing age, the prevalence of 
certain diseases is changing. D’Arcy et al. [2] spoke 
of the “next cardiac epidemic” in 2011 due to the 
increasing prevalence of valvular heart disease, 
particularly aortic stenosis (AS), observed with 
the ageing population. The prevalence of any de-
gree of calcific, degenerative AS consists of up 
to 40% of people aged 80 years and over [3]. 
More importantly, severe symptomatic AS carries 
a poor prognosis if left untreated. With the advance-
ment of trans-catheter techniques, a lower compli-
cation profile and increased world-wide availability 
has meant that more patients are being referred for 
consideration of this treatment. Trans-catheter aortic 
valve implantation (TAVI) is already the mainstream 
therapy for inoperable and high risk AS patients. 
A large number of patients have received this treat-
ment as it has evolved over the past 10 years and in 
Germany in 2015, more patients with aortic valve 
disease received a TAVI rather than surgical aortic 
valve replacement (sAVR). In this article, some light 
is shed on the most recent advances and where the 
future may lie.
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Current utility of trans-catheter  
aortic valve intervention
Transcatheter aortic valve implantation rep-
resents one of the most significant technological 
advances made in cardiovascular medicine over 
the last decade. Since TAVI was first described by 
Alan Crieber in 2002, it has made its way into the 
European Society of Cardiology [4] and American 
Heart Association guidelines [5] (Table 1) and has 
become the ‘standard of care’ for inoperable and 
high risk groups of patients with severe AS. Table 1 
summarizes the current guidelines that refer to TAVI.
In the United Kingdom 3,980 TAVIs were per-
formed before 2012 and the number has increased 
dramatically since with more than 1800 cases done 
during 2014 alone [6]. Whilst in Germany 15,964 
were done between 2011 and 2013 [7], in France 
3,972 [8], between 2010 and 2012 and in the United 
States 12,182 TAVIs were performed between 
November 2011 and June 2013 [9]. Conversely, the 
Asian TAVR registry suggested smaller numbers 
of cases performed in comparison to Europe and 
the United States with 848 cases done in 5 Asians 
countries between March 2011 and September 
2014 [10]. This was largely due to regulatory is-
sues. It is noteworthy that the number of TAVIs 
performed in Germany since 2013 has surpassed 
the number of isolated sAVR cases [11]. Figure 1 
summarizes the upward trend of TAVI in Europe 
per million population as per 2011 [12]; It also 
demonstrates the differences between different 
health care systems. 
Case selection
Whilst there are some variations among cen-
tres/countries, the overall care pathway of pa-
tients undergoing TAVI is relatively standardized. 
Decision-making in the investigation and treat-
ment of these patients is achieved with the ‘Heart 
Team’, a multidisciplinary group of interventional 
cardiologists, cardiothoracic surgeons, imaging 
specialists, anaesthesiologists and care-of-the-
elderly physicians. 
Once a suitable patient is identified, he or she 
completes a thorough work-up that includes multiple 
imagining modalities including trans-thoracic echo-
cardiography, three-dimensional (3D) assessment of 
the aortic annulus (using transesophageal echocardio-
graphy or cardiac computed tomography [CT]), CT 
aortogram and peripheral angiography, coronary angio- 
graphy and pulmonary function testing. Key steps 
in pre-operative imaging include assessment of: 
aortic valve morphology, distribution and extent of 
valve calcification, annular dimensions, dimensions 
of the sinuses and sinotubular function, distance of 
the coronary ostia to the aortic annulus, and periph-
eral artery diameter, calcification and tortuosity.
Annular dimensions are key measurements 
in TAVI valve sizing. Choosing the correct valve 
size is important as undersizing the prosthesis 
can result in device migration and embolization 
or significant paravalvular aortic leak (PVL). On 
the other hand, oversizing increases the risk of 
life threatening complications such as annular 
rupture and the risk of vascular injury as bigger 
Table 1. Summary of European Society of Cardiology and American Heart Association guidelines that 
encompass transcatheter aortic valve implantation (TAVI).
Recommendation Class Level Year 
European Society of Cardiology
TAVI is indicated in patients with severe symptomatic AS who are not suitable  
for AVR as assessed by a ‘Heart Team’ and who are likely to gain improvement  
in their quality of life and to have a life expectancy of more than 1 year after  
consideration of their comorbidities
I B 2012
TAVI should be considered in high-risk patients with severe symptomatic AS who 
may still be suitable for surgery, but in whom TAVI is favoured by a ‘Heart Team’ 
based on the individual risk profile and anatomic suitability
IIa B 2012
American Heart Association
TAVI is recommended in patients who meet an indication for AVR who have  
prohibitive risk of surgical AVR and a predicted post-TAVR survival > 12 months
I B 2014
TAVI is a reasonable alternative to surgical AVR in patients who meet an indication 
for AVR and who have high surgical risk for surgical AVR
IIa B 2014
TAVI is NOT recommended in patients in whom existing comorbidities would  
preclude the expected benefit from correction of AS 
III B 2014
AS — aortic stenosis; AVR — aortic valve replacement; TAVR — transcatheter aortic valve replacement
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delivery systems are needed. Inaccurate valve siz-
ing is also associated with altered valve mechanics. 
Consequent under- or over-expansion of the valve 
leads to redundancy of leaflet tissue or leaflet non-
coaptation resulting in transvalvular regurgitation.
The aortic valve annulus is defined as a virtual 
plane at the level of the hinge points of the three 
cusps and in the majority of cases is elliptical. 
Therefore, the use of a 3D imaging modality that 
allows measurements of the annulus diameter in 
two orthogonal plane as well as measurements of 
the perimeter and area is essential, and thus allows 
for calculation of the ‘virtual’ annulus diameter. 
Many centres perform peripheral 3D con-
structed CT and peripheral angiography to assess 
the suitability of aorto-ileofemoral arterial system 
for trans-femoral TAVI. The default route for TAVI 
is trans-femoral and as such the numbers of non-
trans-femoral cases (subclavian, trans-apical and 
trans-aortic) have declined in recent years.
Once the valve is implanted, operators check 
for any vascular injury, conduction defects, aortic 
regurgitation or pericardial effusion. The absence 
of complications would then herald the end of the 
procedure and the patient is then transferred usually 
to a level 2 care facility for monitoring. Most patients 
are being considered for early discharge (by day 3) 
if no further complications arise. Subsequent to dis-
charge, patients usually have follow up at 4–6 weeks 
with echocardiography and electrocardiogram, and 
then annually thereafter. 
Current devices
Whilst there are several TAVI valves in use 
worldwide, the two prostheses that are supported 
by the largest body of evidence and experience 
are: 1) the balloon expanding Edwards SAPIEN 
(Edwards Lifesciences, Irvine, CA, USA) and 2) the 
self-expanding Medtronic CoreValve (Medtronic, 
Minneapolis, MN, USA). They have different 
characteristics, anatomical requirements and echo-
cardiographic appearances but they both provide 
excellent outcomes with their latest generations, 
the Sapien 3 and Evolute R. 
The original Edwards SAPIEN was a balloon 
expandable device that had a stainless steel support 
frame with a bovine pericardial valve and a fabric 
skirt within it. This device was implanted via 
a transfemoral or transapical/transaortic approach. 
The Sapien XT (made of a cobalt-chromium alloy) 
was delivered on a more sophisticated, lower-
profile delivery system. The third generation of the 
Edwards SAPIEN valve, Sapien 3 has an additional 
outer skirt that has minimized PVL. It also has the 
advantage of an even smaller and ‘double flexing’ 
delivery system — the ‘Commander’™. 
The self-expanding CoreValve is self-centering 
and partially repositionable. It is made of a nitinol 
stent with porcine pericardial leaflets. The nitinol 
stent has three zones. The lower zone that applies 
high radial forces within left ventricular outflow 
tract (LVOT) and the annulus anchoring the valve, 
Figure 1. Summary of the upward trend of transcatheter aortic valve implantation (TAVI) in Europe per million popula-
tion as per 2011.
208 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 2
the middle zone that carries a controlled force to 
avoid jailing the coronary ostia and an upper zone 
with low radial forces which functions to orient 
the valve in the direction of aortic root axis. The 
valve is intended to sit in a supra-annular posi-
tion. The second generation, Evolut R valve, has 
a smaller delivery system, a lower frame height, 
fully recapturable and repositionable and available 
for transfemoral or transaortic routes. 
The ideal TAVI valve would be low profile, 
have minimal risk of PVL and would be fully re-
positionable/retrievable. Newer generation, com-
mercially available devices, have gone some way 
to achieving these goals.
The Lotus Valve (Boston-Scientific, Natick, 
Massachusetts, USA) is pre-mounted on the de-
livery system. It can be retrieved, repositioned 
and redeployed any time prior to release. It is 
delivered via the trans-femoral approach only and 
consists of a woven nitinol frame with valve leaflets 
of bovine pericardium. The ventricular portion of 
the valve is surrounded by an adaptive seal. On de-
ployment, it shortens mechanically in a controlled 
way, providing additional radial strength compared 
to traditional self-expandable nitinol devices. The 
Lotus valve carries a higher rate of post procedural 
pacemaker requirement [13, 14]. 
Direct Flow (Direct Flow Medical, Santa Rosa, 
CA, USA) is a self-expanding valve with a novel 
metal free ‘double ring’ design with two aortic (up-
per) and ventricular (lower) inflatable rings. The 
rings contain non-compliant angioplasty balloon 
technology and are connected by a tubular bridg-
ing system. Each ring can be pressurised (through 
the normal saline/contrast) independently to allow 
for inflating/deflating the rings and hence retrieval 
before deployment. After obtaining the optimal 
position, the rings are filled with a polymer. The 
bovine pericardial valve is attached to a cuff that 
conforms to the annulus. Owing to the speed of 
deployment, Direct Flow does not require rapid 
pacing. It provides excellent sealing but suffers 
from higher gradient. Direct Flow is available only 
for the transfemoral approach. 
The Portico valve (St. Jude Medical, Min-
neapolis, MN, USA) is a nitinol self-expanding 
re-sheathable device which consists of bovine 
pericardial leaflets and a porcine pericardial seal-
ing cuff. It is similar to the Evolut R and provides 
open stent cell design to allow access to coronary 
arteries.
The Symetis Acurate (Symetis SA, Ecublens, 
Switzerland) is another self-expanding nitinol stent 
valve with porcine pericardial leaflets which are 
available for both trans-apical and trans-femoral 
approaches. This valve has an upper crown for su-
pra-annular anchoring to minimize protrusion into 
left ventricle and a lower crown that is designed 
to protrude only minimally into the LVOT. It has 
inner and outer pericardial skirts to minimize PVL.
The JenaValve (JenaValve Technology GmbH, 
Munich, Germany) is a self-expanding valve con-
sisting of porcine pericardial leaflets attached to 
a crown shaped self-expanding nitinol stent. It has 
three ‘feelers’ which are to be seated in the aortic 
sinuses at the base of native leaflets. The feelers in 
combination with the stent arms in the lower part 
of the prosthesis allow clipping the native valve 
leaflets which enable operators to accurately posi-
tion the prosthesis. Rapid pacing is not required 
during prosthesis positioning and release. It can 
be used with both trans-femoral and trans-apical 
approaches. The clipping mechanism is particu-
larly useful in non-calcified valves or when aortic 
regurgitation is the primary pathology. 
Tables 2 and 3 summarize some features of the 
commonly available prostheses and their delivery 
systems. 
Potential complications
Vascular injury
The risk of significant vascular damage has de-
creased with lower profile valve delivery systems, 
but remains around 5–8%. By default, trans-femoral 
cases are usually fully percutaneous nowadays 
when previously the femoral arteriotomy was 
a direct surgical cut-down. The omission of these 
traumatic surgical steps have meant that patients 
can undergo TAVI under conscious sedation as op-
pose to general anaesthesia and there is a general 
trend towards a less invasive, conscious sedation 
approach across the world. The fully percutaneous 
approach, including ultrasound-guided puncture of 
the femoral artery and the use of pre-closure suture 
systems have also refined the technique.
The two main vascular closure devices (VCD) 
that have been used in TAVI are the ProStar XL 
(Abbott, Vascular, Santa Clara, California) and 
PerClose ProGlide (Abbott, Vascular, Santa Clara, 
California). These are suture-based devices and 
they replicate surgical closure. The devices were 
tested in interventional radiology randomized 
clinical trials that concluded their safe and effective 
use and non-inferiority to open surgical cut-down 
(PEVAR trial [15]). 
In TAVI, the use of VCD improved procedure 
safety and reduced complications, however the 
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data on the best VCD in TAVI is still contradic-
tory. An awareness of potential harm with check 
angiography and ‘cross-over’ access from the con-
tralateral side has improved safety in this regard. 
The current evidence is that the use of VCDs has 
a learning curve and in experienced hands they 
are effective, reduce complications and are likely 
to influence early mobility and discharge of TAVI 
patients [16, 17]. 
Paravalvular aortic leak
Paravalvular aortic leak is an important com-
plication of TAVI that is associated with increased 
mortality for both balloon-expandable and self-
expanding valves. In early series, TAVI was as-
sociated with PVL in more than 80% of patients. 
PVL was common with earlier valve designs as 
a result of incomplete apposition of the prosthesis 
to the aortic annulus. The principal contributing 
mechanisms were undersized prostheses, sub-
optimal positioning and/or challenging anatomy of 
the aortic root and valve (e.g. eccentric or heavy 
calcification). 
The incidence of moderate or severe PVL has 
been reported to be between 2% and 17% in ran-
domized trials and major registries. Many studies 
have shown that PVL predicts increased mortal-
ity [18, 19] and have emphasized that it should be 
minimized or avoided if at all possible. More so-
phisticated aortic annulus sizing (with 3D imaging 
Table 2. Prostheses types and their main advantages (according to manufancturer).
Device Manufacturer Size [mm] Deployment Main advantage
Sapien XT Edwards  
Lifesciences
20–29 Balloon expandable Studied in large scale trials 
Sapien S3 Edwards  
Lifesciences
20–29 Balloon expandable Low profile delivery system 
Distal skirt that reduces PVL
CoreValve Medtronic 23–31 Self-expanding Studied in large trials
CoreValve Evolut R Medtronic 23–29 Self-expanding Low profile delivery system
Lotus Valve Boston Scientific 23–27 Mechanical  
expansion
Repositionable  
and retrievable valve
Portico St. Jude Medical 23–25 Self-expanding Low profile delivery system 
Repositionable  
and retrievable valve
Direct Flow Direct Flow  
Medical
25–29 Inflatable aortic and 
ventricular rings 
Optimal control  
over deployment 
CENTERA Edwards  
Lifesciences
23–26 Motorised  
expansion
Ultra-low profile  
delivery system
PVL — paravalvular aortic leak
Table 3. Examples of some of the available delivery systems.
Prosthesis Size [mm] Delivery system Femoral sheath size
Sapien XT 20 NovaFlex 16 Fr eSheath
Sapien S3 23 Commander 14 Fr eSheath
26 Commander 14 Fr eSheath
29 Commander 16 Fr eSheath
CoreValve 23 DCS-C4-18FR-23 18 Fr
26–31 DCS-C4-18FR 18 Fr
Evolut R 23–29 EnVeo R 14Fr-eqivalent 14 Fr
Lotus 23 Lotus valve system 18 Fr
26–29 Lotus valve system 20 Fr
Portico 23–25 Portico TF delivery system 18 Fr
Direct Flow 25–27 Direct Flow delivery system 18 Fr
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modalities), various technological advances, such 
as the addition of a ‘sealing’ skirt to the frame of the 
valve as with Sapien 3, and judicious use of post-
dilatation are examples of the concerted efforts to 
tackle this particular complication. Further studies 
are needed to verify exactly why paravalvular aortic 
regurgitation has such a negative effect on survival.
Permanent pacemaker requirement
The risk of significant conduction disturbance 
following TAVI is 10–25%. The incidence is vari-
able for different devices as some have a higher 
pacemaker requirement with the valves than oth-
ers [20, 21]. This has been addressed with device 
design and also positioning within the native aortic 
valve. There is some evidence to suggest that 
a higher prosthesis implantation lessens the inci-
dence of complete heart block [20].
Stroke
The incidence of stroke after TAVI is between 
1.7% and 8.4% depending on the clinical definition. 
Strokes after TAVI may differ in nature from those 
after sAVR. It is possible that showers of cerebral 
emboli at different time-points during TAVI cause 
a more diffuse brain injury manifesting as a subtle 
cognitive impairment rather than an overt neuro-
logical event such as hemiplegia. These kinds of 
events are difficult to diagnose and indeed adjudi-
cate in clinical trials.
There are a number of cerebral ‘embolic pro-
tection/deflection’ devices currently available to 
reduce the risk of cerebral micro-embolization. 
The application of these devices requires extra 
caution and is only advised in certain high risk 
groups of patients. 
Ventricular injury
Left and right ventricular injury peri-proce-
durally is well documented. Whilst the injury is 
usually traumatic, coronary obstruction as a cause 
of ventricular injury (peri-procedural myocardial 
infarction) has also been referred to, the rate of 
which is less than 1% [22]. Right ventricular 
injury is commonly caused by the temporary 
pacing wire perforation, and left ventricular in-
jury is caused by the stiff wire perforation but 
a much rarer complication. Traumatic left or right 
ventricular injury usually manifests itself with 
pericardial effusion and tamponade. The rate of 
pericardial effusion and tamponade peri-TAVI is 
reported to be around 4% [23, 24]. Of note, in 
a series of cases, only 4 (23.5% of all causes of tam-
ponade) were attributed to direct left ventricular 
wire perforation [24].
Overall, the complication rate associated with 
TAVI is decreasing with the advancement of tech-
nology and accumulating experience. The rates of 
stroke, bleeding and vascular complications in real 
life registries appear to be lower than that of the tri-
als. The rates are likely to drop further once TAVI 
is performed more in intermediate risk patients. 
Table 4 lists the reported complications according 
to the corresponding trial and registry. 
Table 4. Rate of complications as per trials and registries.
Year CVA Pacing Vascular Bleeding AKI
Trial
PARTNER B [31] 2010 6.7% 3.4% 30.7% 16.8%$ 0
PARTNER A [32] 2011 5.5% 3.8% 17% 9.3%$ 1.2%
CoreValve Extreme Risk [33] 2014 4% 21.6% 8.2% 12.7%* 11.8%
CoreValve High Risk [34] 2014 4.9% 19.8% 5.9% 13.6%* 6%
PARTNER II [35] 2016 6.4% 8.5% 7.9% 10.4%* 1.3%
NOTION [36] 2015 2.8% 34.1% 5.6% 11.3% 0.7%
Registry
FRANCE II [8] 2012 4.1% 15.6% 4.7% 1.2%* N/R
UK TAVI [6] 2016 2.6% 10.2% 3.5% N/R N/R
STS/AAC# [9] 2014^ 2.2% 11% 4.2% 4.3% 2.2%
GARY# [7] 2015 1.5% 17.5% 4.1% 26.3% N/R
Asian# [10] 2016 3.8% 9.5% 5%$ 6.4%* 3.3%
Australian-New Zealand [37] 2014 5.3% 28.4% 7.6% 7% 6.5%
$Major bleeding; *Life threatening or disabling bleed; ^Outcomes of year 2014; #In-hospital outcomes; CVA — cerebrovascular accident;  
AKI — acute kidney injury; N/R — not reported
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Table 6. Unpcoming randomised clinical trials in transcatheter aortic valve implantation (TAVI).
Trial Objective Date of completion 
PARTNER 3 To determine safety and effectiveness of Sapien 3 in low risk  
patients in comparison to sAVR
2027
UK TAVI To determine clinical effectiveness and cost-utility of TAVI  
in comparison to sAVR (high and intermediate risk)
2016
ACTIVATION Percutaneous coronary intervention prior to TAVI
GALILEO Effect of rivaroxaban anticoagulation strategy in comparison  
to dual anti-platelet therapy
2018
TAVR UNLOAD To determine safety and efficacy of TAVI in patients with  
moderate aortic stenosis and heart failure in comparison  
to optimal medical therapy 
2020
STEP for patients 
prior to undergoing 
TAVR 
Whether supervized exercise would improve frailty status  
of TAVI patients 
2017
sAVR — surgical aortic valve replacement; TAVR — transcatheter aortic valve replacement
Table 5. A summary of the major completed transcatheter aortic valve implantation (TAVI) trials.
Randomised trial Objective Patients Prosthesis Year Outcome
PARTNER B TAVI superior to  
optimal medical  
therapy in non-operable 
severe AS patients 
358 Edwards Sapien 2010 Significant reduction  
in mortality and  
hospitalization 
PARTNER A TAVI is non-inferior  
to sAVR in high risk 
surgical patients
699 Edwards Sapien 2011 TAVI and sAVR have 
similar rates of  
mortality at 1 year
PARTNER 2 TAVI is non-inferior to 
sAVR in intermediate 
risk patients
2032 Edwards  
Sapien XT
2016 TAVI is non-inferior  
in terms of mortality 
and stroke
CoreValve Pivotal  
high risk trial
TAVI is non-inferior 
and superior to sAVR
795 CoreValve 2014 TAVI is superior  
to sAVR
CoreValve Pivotal  
extreme risk trial
TAVI is superior to  
optimal medical therapy
506 CoreValve 2014 TAVI is safe and  
effective
NOTION trial TAVI is non-inferior to 
sAVR in all comers
280 CoreValve 2015 TAVI is non-inferior  
to sAVR
DEFLECT III trial [38] TriGuard cerebral  
protection evaluation
85 Edwards Sapien 
and CoreValve
2015 TriGuard is safe and  
effective
BRAVO-3 trial [39] Bivalirudin vs. heparin 
in TAVI
802 Multiple 2015 Bivalirudin does not  
reduce bleeding
EMBOL-X [40] Intra-aortic protection 
device
30 Sapien XT 2015 Reduced cerebral  
lesions
AS — aortic stenosis; sAVR — surgical aortic valve replacement
Current evidence
The number of randomized trials involving 
TAVI is rising, and whilst initially the main objec-
tives of the trials were to demonstrate its non-
inferiority to sAVR, current trials also compare 
different strategies in TAVI (Table 5). These rand-
omized trials thus far have certainly demonstrated 
non-inferiority to sAVR in terms of mortality and 
stroke in high and intermediate risk patients and 
superiority to optimal medical therapy. 
Upcoming trials
Table 6 shows examples of the upcoming ran-
domized clinical trials in TAVI [25]. The topics and 
the research questions that are being asked have 
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varied more recently and ask questions beyond 
merely demonstrating the efficacy of the technique. 
Evidence from registries
The uptake of TAVI technology is increasing 
worldwide. Registries around the world are regu-
larly publishing and updating their experience with 
TAVI. One-year mortality is somehow variable 
among different countries but the rate of stroke 
seems more consistent. Both outcome measures 
have decreased in recent years. Table 7 summa-
rizes the two main outcomes (mortality and stroke) 
at 1 year reported by these registries according to 
their most recent publications.
Cost-effectiveness of TAVI
The debate over cost-effectiveness of TAVI is 
complicated with the following issues: 
 — The characteristics of the patients who are 
deemed suitable for TAVI (high risk elderly 
patients with multiple comorbidities);
 — The life expectancy is relatively short for 
these patients even with successful treatment;
 — The duration of economic modeling;
 — The control group (TAVI vs. optimal medical 
therapy, and TAVI vs. sAVR);
 — The healthcare/reimbursement system studied.
The index procedure of TAVI is more ex-
pensive than sAVR and any cost saving earned is 
usually through lower cost of hospitalization and 
follow-up. In the United Kingdom (Aug 2013), TAVI 
was found to be cost-effective when compared 
to optimal medical therapy (patients who were 
unsuitable for sAVR), but more costly and less 
effective when compared to sAVR (patients who 
were suitable for sAVR) [26]. Reynolds et al. [27] 
studied the PARTNER A cohort and concluded that 
trans-femoral TAVI was an attractive option when 
compared to sAVR but not transapical TAVI. When 
self-expanding prosthesis TAVI was compared to 
sAVR (CoreValve US. pivotal trial cohort), the 
authors concluded that TAVI provided meaningful 
clinical benefits with incremental costs considered 
acceptable by United States standards [28]. 
In summary, TAVI seems cost-effective when 
compared to medical therapy. Trans-femoral TAVI 
also seems cost-effective when compared to sAVR. 
It is very likely that the tide will shift in favour of 
TAVI when competition for alternative devices 
drives down device prices.
What lies ahead?
Arguably, the most frequently asked question 
in the TAVI arena is what happens to these pros-
theses long-term? 
Dvir et al. [29] reported crude data in 2016 
which suggested a 50% prosthesis degeneration 
rate within 8 years of implant. However, the num-
ber of cases at risk in the study was only 43 at 
6 years and only 7 cases at 8 years. The jury is 
still out on this and future publications have much 
to add. The general feeling in the cardiology com-
munity is that TAVI prostheses are as durable 
a surgical bioprostheses although further research 
on this subject is eagerly awaited.
Considering recent results of PARTNER II and 
other intermediate risk studies such as UK TAVI 
and SURTAVI, it is very likely that the indications 
of TAVI will expand to cover intermediate risk 
patients, thus increasing the number of TAVIs 
worldwide even further. The expected increase in 
the uptake of TAVI will be consolidated by lower 
profile delivery systems, and predictable, reposi-
tionable and retrievable prostheses. 
On the other hand, clinical practice simplifica-
tion of the procedure (such as the introduction of 
conscious sedation, fully percutaneous approach 
and early mobility post TAVI) is likely to increase 
early discharge rates [30]. This approach is likely to 
make TAVI an even more cost-effective technique 
and more appealing to patients who are usually 
keen for quick recovery after a procedure.
Table 7. Reported registries’ outcome.
Registry Country Cases Year Mortality  
at 1 year
Stroke
FRANCE II France 3,195 2012 24% 4.1%
STS/AAC United States of America 12,182 2015 23.7% 4.1%
GARY Germany 3,876 2014 24.3% 4.2%
UK TAVI United Kingdom 3671 2015 18.3%
Asian TAVR Multiple 848 2016 10.8% 3.8%
Australian-New Zealand Australia, New Zealand 540 2014 11.9% 8.2%
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Unanswered questions about co-morbidities 
such as co-existing coronary artery disease, mitral 
valve disease and pulmonary hypertension are 
likely to be clarified in the near future by further 
research (randomized and observational). 
Finally, much of TAVI technology and ex-
perience is being utilized in the development of 
trans-catheter mitral valve interventions, the 
long-waited and expected next era of trans-catheter 
intervention.
Conclusions
Transcatheter aortic valve implantation is now 
a well-established therapy for aortic valve disease. 
The procedure is being simplified, the complication 
rate is being reduced and indications are expanding. 
It is an increasingly cost-effective treatment and 
is likely to become a first line option in the treat-
ment of AS, particularly as device costs fall in the 
years to come. 
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